Targeting Tie2 to Treat Diabetic Nephropathy

Project: Research project

Project Details


Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) in developed countries [1]. In the United States, nearly 200, 000 patients are treated with ESRD care due toDN, with 50, 000 new patients starting dialysis each year. Whereas DN is a major problem in healthcare, there are only limited options for treatments [1], underscoring an urgent need to develop new therapies forthis devastating disease. Recent studies identified that aberrant activation of endothelial cells, which leads to sustained inflammation, is central to the pathogenesis and progression of diabetic complicationsincluding DN [2, 3]. Thus, identification of pathways that normalize endothelial cell health is an attractivestrategy to develop treatments.
Effective start/end date9/1/158/31/16


  • Mallinckrodt Medical, Inc. (Agmt 9/01/15)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.